Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist derived from the GLP-1 backbone, with substitutions and an acylated side chain that confer prolonged circulation
The first human-based GLP-1RA to be evaluated in clinical trials for OW dosing was taspoglutide (BIM-51077, Aib8,35 GLP-1 [7-36] amide, Roche)
Small lumps or nodules Occasionally, a small lump forms at the injection site
MedVi doesn't publish aggregate outcome statistics in the same way, but the platform's scale speaks for itself
Genetic testing through the Precision Peptide panel reveals your unique peptide-pathway predispositions, helping clinicians adjust your semaglutide regimen for faster, more sustainable results
Quick Answer: Current evidence does not show that GLP-1 receptor agonists cause blood clots or increase the risk of venous thromboembolism